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Background: There is evidence supporting the use of extracorporeal shock wave therapy (ESWT) in calcific
tendinopathy of the rotator cuff, but the best current evidence does not support its use in non-calcifying
tendinopathy. We conducted a randomized placebo-controlled trial to investigate the efficacy and safety of low
energy ESWT for non-calcifying tendinopathy of the rotator cuff.
Methods: 20 patients with non-calcifying supraspinatus tendinopathy (NCST) were randomized to an active or a
sham treatment group. Physical, blood, roentgenographic, and MRI examinations of the shoulder were conducted
to verify that patients met the inclusion and exclusion criteria. These examinations were repeated six and twelve
weeks after treatments. Effectiveness was determined by comparison of the mean improvement in the Constant
and Murley score (CMS) between the treatment and the placebo groups at three months. Safety was assessed by
analyzing the number and severity of adverse events.
Results: All the patients completed the investigation protocol. At the final follow-up, significant improvement in the
total CMS score and most of the CMS subscales was observed in the ESWT group when compared to the baseline
values. Significantly higher total CMS, and significantly higher scores for CMS pain and ROM were observed in the
ESWT group when compared to the placebo. No serious adverse events were noted after ESWT.
Conclusions: Patients suffering from NCST may benefit from low energy ESWT, at least in short-term. The
application protocol of ESWT is likely to play a key-role in a successful treatment. Future investigations should be
undertaken on the long-term effects of this technique for the treatment of NCST.
Trial registration: Current Controlled Trials ISRCTN41236511Background
Supraspinatus tendinopathy is a common and disabling
condition that becomes more prevalent after middle age
[1,2]. There exist many forms of conservative treatment
but evidence for their efficacy is not well established [3].
The shock wave is a single-impulse acoustic wave gen-
erated by an electromagnetic, electrohydraulic or piezo-
electric source. The energy at the focal point is recorded
in millijoules per area (mJ/mm2) and based on this value,* Correspondence: galasso@unicz.it
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reproduction in any medium, provided the orshock waves are classified as low, medium, or high en-
ergy [4]. In the last 20 years extracorporeal shock wave
therapy (ESWT) has been widely used to treat entheso-
pathies [5,6]. Trials have examined the effect of ESWT
on plantar fasciitis [7], epicondilytis [8] and jumper’s
knee [9]. Good evidence is available to support the use
of extracorporeal shock wave therapy (ESWT) in calcific
tendinopathy of the rotator cuff, but the best current evi-
dence does not support its use in non-calcifying tendino-
pathy of the rotator cuff [10]. However, only a limited
number of studies have reported on ESWT for non-calci-
fying supraspinatus tendinopathy (NCST) in the English
literature [11-13].Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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safety of low energy ESWT in patients suffering from
chronic NCST and compared it to placebo. Effectiveness
was determined by comparison of the mean improve-
ment in the Constant and Murley score (CMS) in the
treatment and the placebo groups at three months.
Roentgenographic and MRI changes of the shoulder both
within and between the two groups were evaluated at
follow-up. Safety was assessed by analyzing the number
and severity of adverse events associated with use of the
investigational treatment.Methods
Patients
The study protocol was approved by the local Ethics
Committee and the research was carried out in compli-
ance with the Helsinki Declaration. Patients with NCST
who had failed conservative treatments for a minimum
of four months were evaluated for enrollment in the
study. The prior regimens of conservative treatments
included: administration of at least one subacromial ster-
oid injection, one course of non-pharmacological therapy
for at least 3 weeks, and one course of non-steroidal
anti-inflammatory drugs or analgesics. The clinical cri-
teria to diagnose the supraspinatus tendinopathy were a
minimum six-month period of painful shoulder and pain
on the Jobe [14] or full can tests [15]. The can test con-
sists in evaluating the patient’s ability to resist downward
pressure on the arms held at 90° elevation in the scapular
plane and 45° external rotation [15]. A screening inter-
view with physical and blood examinations, an X-ray
and an MRI of the shoulder were conducted to ensure
that the referred patients met the inclusion and exclu-
sion criteria (Table 1) and were willing to participate to
the study. Informed consent was obtained subsequently.
The blood examination consisted of a complete blood
count, prothrombin time, partial thromboplastin time,
and a pregnancy test for women of child-bearing poten-
tial. A general physical examination and CMS [16,17]
were measured by an orthopedic surgeon blinded with
respect to the treatment regimen of each patient. The
CMS combines subjective and objective measurements
in one score. The objective parameters (65 points) in-
clude the patient’s range of motion (ROM) and power,
corresponding to the number of pounds of force recorded
by the dynamometer. A static strength tester (CSD 300
Chatillon - Ametek Inc., U.S.A.) was used. The subjective
parameters included pain and impact on activities of daily
living (ADL), including positioning (35 points). The CMS
increases as pain decreases and shoulder mobility
increases, therefore the higher the CMS, the greater the
improvement in the condition and quality of life of the
patient. The CMS has been extensively validated andshows good intra- and inter-observer reproducibility [16-
18].
Patients were considered a treatment success if they
showed an improvement of at least 30 points, or their
CMS at the study’s endpoint was at least 80% of the
standard age- and gender-related value [11,19]. Patients
observed a pain medication-free interval 3 days prior to
each CMS evaluation. Baseline social, anthropometric,
educational, and occupational variables that might be
associated with the outcome were gathered through a
study-specific questionnaire. After treatment and during
follow-up, patients were restricted to the use a 1000 mg
of acetaminophen per day in cases of pain, in order to fa-
cilitate comparison of the medications and usage among
the patients and groups and across all follow-up visits.
The patients were randomized to an active or sham
treatment group using stratified random permuted
blocks with an allocation ratio of 1:1 and they were un-
aware whether they had received treatment. One patient
initially assigned to the placebo group was lost after
randomization, thus leaving twenty individuals available
for the study (i.e. 11 in the ESWT and 9 in the placebo
group). The study did not allow for crossover. The
cohorts were scheduled at different times to ensure that
the individuals within the cohorts did not contact each
other.
Imaging studies
The X-ray exams consisted of anteroposterior and
supraspinatus outlet views. Magnetic resonance imaging
scans (Siemens Magnetom Synphony-Maestro-Class,
1,5T) were acquired for all patients and included: a fast
spin-echo intermediate-weighted axial sequence, a fast
spin-echo coronal oblique intermediate-weighted se-
quence, and coronal oblique and sagittal oblique fast
spin-echo T2-weighted acquisitions with fat suppression.
A supraspinatus tendinopathy was diagnosed if inter-
mediate-weighted and T2-weighted images showed dif-
fuse mildly increased signal intensity (not equal to that
of fluid) and an intact tendon was observed [20]. A full-
thickness tear was defined as a high T2 signal extending
through the depth of the tendon [21]. X-rays and MRI
studies were independently evaluated by two musculo-
skeletal radiologists, who were unaware of the clinical
characteristics of the patients, and the same measure-
ments were repeated twice on two separate days.
Cohen’s kappa coefficient for inter-observer and intra-
observer reliability of scoring was 0.78 and 0.80, respect-
ively. A consensus decision on the scores was reached in
a final common readout.
Interventions
The ModulithW SLK system (Storz Medical AG, Tagerwilen,
Switzerland) was the electromagnetic therapy source used
Table 1 Inclusion and exclusion criteria
Inclusion Criteria Exclusion criteria
1. Male and non-pregnant female patients 18 years of age or older
(women of child-bearing potential must have a negative serum
pregnancy test performed within 1-14 days prior to the treatment
procedure) suffering from NCST as diagnosed by X-ray, MRI and
physical examination.
1. Patient has a history of uncontrolled severe hypertension
(systolic pressure > 180 mmHg, diastolic pressure > 110 mmHg).
2. Patient has not responded to a standard course of non-pharmacological
and non-surgical conservative treatment for a minimum of three weeks.
The treatment above consists of: therapeutic exercise, and/or ultrasound,
and/or iontophoresis, and/or cryotherapy, and/or immobilization or
activity modification.
2. Patient has unstable or uncontrolled angina, uncontrolled heart
failure, or serious uncontrolled ventricular arrhythmias.
3. Patient has not responded to pharmacological treatment (one course
of the standard dose of prescribed analgesic or NSAID) and has had
at least one subacromial steroid injection.
3. Patient has a white blood cell count less than 2,000 or greater than
15,000, or platelet count less than 50,000.
4. Diagnosis of supraspinatus tendinopathy is only in one shoulder. 4. Patient has a known bleeding disorder or is currently being treated
with anticoagulant therapy.
5. Patient has free passive range of movement and at least 90 degrees
active abduction in the affected shoulder.
5. Patient is currently being treated with a narcotic or NSAIDs and/or
has used analgesics or NSAIDs within the 72 hours prior to the SV.
6. Patient is willing to participate in the study and return for all scheduled
follow-up visits.
6. Patient has participated in any other shoulder pain treatment
research study within 30 days prior to the SV.
7. Patient is capable of giving, and has given, written informed consent. 7. Patient had prior shoulder surgery
8. Patient received prior ESWT for any disease.
9. Patient is complaining of pain in both shoulders.
10. Patient has malignant tumors, irrespective of location.
11. Patient has a cardiac pacemaker implant.
12. Patient has anatomy that prevents the focusing of the device into
the shoulder in the area of the supraspinatus tendon (e.g., extensive
scarring, misalignment of previous fractures, non-unions or delayed
fracture healing, congenital malformation, etc.).
13. Patient has any upper extremity neurological disorder as diagnosed
from focused neurological exam and neurophysiological studies
(e.g. thoracic outlet syndrome, reflex sympathetic dystrophy, etc.).
14. Patient has a full-thickness rotator cuff tear of any of the rotator cuff
tendons as seen on MRI.
15. Patient has an acromiohumeral interval less than 7mm as measured
on a standard AP X-ray, or severe symptomatic degenerative changes in
the glenohumeral or acromioclavicular joint.
16. Patient has acute subacromial bursitis as diagnosed by MRI
17. Patient has generalized polyarthritis, rheumatoid arthritis.
18. Patient is allergic to local anaesthetic.
SV, indicates screening visit; NCST, non-calcific supraspinatus tendinopathy; AP, Anteroposterior; NSAIDs, Non-Steroidal Anti-Inflammatory Drugs.
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achieved by means of an in-line 7.5 MHz ultrasound trans-
ducer with a scanning depth range of 3-15 cm, located in
the center of the therapy source. Shock waves were focused
at an area 1 cm proximal to the insertion of the tendon in
the bone, with the patient in a supine position. The treat-
ment regimen required administration of two treatment ses-
sions, each consisting of 3000 shockwaves at an energy flux
density of 0.068 mJ/mm2, separated by a 7-day interval. A
similar protocol showed to be effective in the treatment of
calcific shoulder tendinopathy [22]. The sham treatment
entailed use of the same device in which the shockwave
generator was disconnected. A compact disc player with a
prerecorded sound of the ramp-up shocks produced thesound characteristic of the device as if it had been normally
activated. The speakers were stored under the upper cover
of the shock wave generator. As shockwaves may cause pain
and discomfort, patients in both groups received a subcuta-
neous injection of 2cc of 2% lidocaine above the subacro-
mial space of the affected shoulder prior to each treatment.
The patient was treated by an unblinded investigator not
involved in the enrollment of the patients, their
randomization, or their follow-up. The heart rate, blood
pressure, body temperature, and respiration rate were mea-
sured before and immediately after each treatment. Treat-
ments were performed as outpatient procedures.
Patients repeated the physical and blood examination
and the CMS evaluation at both 6 and 12 weeks follow-
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repeated. The use of shoulder pain medication or any
other drug was recorded at the final treatment and dur-
ing the follow-up period. Adverse effects were assessed
by clinical examination and by a patient questionnaire
directly after the ESWT/sham procedure and at every
follow-up visit. An anticipated adverse device effect
(Anticipated adverse event for ESWT) was considered an
adverse event that had been previously identified as oc-
curring with some frequency as a result of the device
use; conversely, an unanticipated adverse device effect
was one that had not been identified in its nature, sever-
ity, or frequency in the literature. Adverse events were
evaluated by the investigator blinded to patient assign-
ment. The patient’s subjective opinion of the treatment
received was noted at the study’s conclusion. All findings
were recorded on standardized forms. At the final fol-
low-up, the patients in the control group still com-
plaining of symptoms of supraspinatus tendinopathy
were offered the real ESWT, while those in the active
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Right 7 6 0.999†
Left 4 3
†Anticipated adverse event for ESWT
Subcutaneous hematoma at treatment site
Petechiae at treatment site
Ecchymosis at treatment site
Increased pain in treated shoulder
Skin redness at treatment site
Bleeding
Swelling of treated shoulder





A telephone recall of the ESWT patients was carried
out nine years after treatment to collect data about the
number of patients who eventually progressed to surgical
intervention or other treatment options. At the same
time, the satisfaction with ESWT and willingness to




Type I 8 7 0.999†
Type II 2 2
Type III 1 0
*The values are given as mean ± standard deviation (range).
ESWT, extracorporeal shock wave therapy; BMI, body mass index; ST,
supraspinatus tendon.
} Unpaired t-test.
† Monte Carlo or Fisher exact test.
{ Mann-Whitney U-test.Statistical analysis
Mean, standard deviation and range were reported for the
continuous variables, whereas counts described the cat-
egorical variables. Because of the low expected frequencies,
a Monte Carlo method or Fisher’s exact test was used for
testing the significance of comparisons of the categorical
variables between the ESWT group and the control sub-
jects. An unpaired t-test was used to compare the means
of quantitative variables between the groups.Due to the non-normal distribution, non-parametric
tests were used to compare the obtained shoulder ratings
before and three months after starting the treatment,
and between the ESWT and placebo groups. In particu-
lar, a Mann-Whitney U-test was used to assess the differ-
ence in scores distributions between the treatment and
placebo groups, whereas a Wilcoxon test was used to
compare the scores before and after the initiation of
treatment. To calculate the power (1 – β error probabil-
ity; two tailed) achieved by our statistical tests, we con-
sidered the actual sample size, the observed effect size,
and the α value = 0.05.
SPSS (version 17.0, SPSS Inc., Chicago, USA) and
G*Power (Institut fur Experimentelle Psychologie, Hein-
rich Heine Universitat, Dusseldorf, Germany) software
were used for the statistical analyses.
Results
All the patients completed the investigation protocol.
The baseline characteristics of the study population are
shown in Table 2. The demographic and all clinical data
except the BMI did not differ between the ESWT group
and the placebo group at baseline. No significant differ-
ences on the physical parameters were noted immedi-
ately after treatments within and between the two
groups of the study. As shown in Table 3, at the earlier
follow-up significant CMS changes were noted only in
Table 4 Comparison of shoulder ratings before and 3
months after ESWT/sham treatment in the study and
placebo groups
CMS ESWT PLACEBO P value1
PAIN
Baseline 2.72 ± 2.61 (0-5) 3.33 ± 2.5 (0-5) 0.592
3 months 10.9 ± 4.37 (5-15) 6.11 ± 4.86 (0-15) 0.039
P value2 0.004 0.096
ADL
Baseline 10.27 ± 3.28 (5-18) 11.55 ± 4.21 (6-18) 0.378
3 months 17 ± 4.22 (8-20) 12 ± 5.63 (4-20) 0.059
P value2 0.005 0.779
ROM
Baseline 16.18 ± 4.68 (10-24) 16.67 ± 8.36 (2-26) 0.878
3 months 30.9 ± 9.05 (16-40) 18.22 ± 10.50 (6-36) 0.012
P value2 0.005 0.635
POWER
Baseline 13.27 ± 5.40 (5-20) 10.11 ± 3.18 (5-15) 0.170
3 months 15.27 ± 6 (6-23) 11.67 ± 3.46 (6-16) 0.170
2
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and the placebo group showed significant differences for
the total CMS and the ROM subscale. At the final fol-
low-up (Table 4), significant improvement in the total
CMS and all the subscales (except power) was observed
in the ESWT group when compared to the baseline
values. In contrast, within the placebo group no statisti-
cally significant differences were observed with baseline.
When the groups were compared, significantly higher
total CMS and significantly higher scores for pain and
ROM were observed in the ESWT group. The number
and percentage of successful treatments according to the
different study groups at the final follow-up are shown
in Table 5. The mean relative improvement in the total
CMS at three months was significantly higher in the ac-
tive treatment group than in the control group (74.5%
and 15.2% respectively, p = 0.014).
No relevant adverse effects occurred during or after
treatment, but there was a slight pain increase. Indeed,
in the ESWT group, one patient reported a short-lived
and bearable pain increase during the second session ofTable 3 Comparison of shoulder ratings before and 6
weeks after ESWT/sham treatment in the study or
placebo groups
CMS ESWT PLACEBO P value1
PAIN
Baseline 2.72 ± 2.61 (0-5) 3.33 ± 2.5 (0-5) 0.592
6 weeks 8.18 ± 3.37 (5-15) 4.44 ± 3.9 (0-10) 0.045
P value2 0.006 0.414
ADL
Baseline 10.27 ± 3.28 (5-18) 11.55 ± 4.21 (6-18) 0.378
6 weeks 15.1 ± 3.83 (7-20) 11 ± 5.48 (2-20) 0.068
P value2 0.01 0.674
ROM
Baseline 16.18 ± 4.68 (10-24) 16.67 ± 8.36 (2-26) 0.878
6 weeks 27.27 ± 8.5 (12-40) 17.1 ± 9.06 (8-32) 0.038
P value2 0.006 0.618
POWER
Baseline 13.27 ± 5.4 (5-20) 10.11 ± 3.18 (5-15) 0.170
6 weeks 13.36 ± 4.3 (7-18) 10.55 ± 4.21 (6-19) 0.174
P value2 0.834 0.726
TOTAL
Baseline 42.45 ± 9.83 (29-61) 41.67 ± 12.53 (20-57) 0.970
6 weeks 64 ± 16.6 (32-87) 43.11 ± 19.16 (18-70) 0.018
P value2 0.004 0.368
The values are given as mean± standard deviation (range).
1 Comparison between treatment and control group both before and after
treatment (Mann-Whitney U- test).
2 Comparison between before and after treatment within each group
(Wilcoxon test).
ESWT, indicates extracorporeal shock wave therapy; ADL, activity of daily living;
ROM, range of motion; CMS, Constant and Murley Score.
P value 0.096 0.119
TOTAL
Baseline 42.45 ± 9.83 (29-61) 41.67 ± 12.53 (20-57) 0.970
3 months 74.09 ± 20.56 (39-98) 48 ± 22.3 (17-79) 0.023
P value2 0.003 0.260
The values are given as mean ± standard deviation (range).
1 Comparison between treatment and control group both before and after
treatment (Mann-Whitney U- test).
2 Comparison between before and after treatment within each group
(Wilcoxon test).
ESWT, indicates extracorporeal shock wave therapy; ADL, activity of daily living;
ROM, range of motion; CMS, Constant and Murley Score.therapy, while two patients reported an increase in pain
at final follow-up. In the placebo group an increase was
noted by only one patient, at three months after
treatment.
As for the medications the patients used after treat-
ment and during follow-up, the use of acetaminophen in
the ESWT and placebo group averaged 0,73 ± 1,68 (range
0-5) and 6,78 ± 13,46 (range 0-41) days, respectively, but
the difference was not statistically significant (p = 0.16).
Seven out of eleven and five out of nine patients believed
they had received active treatment in the ESWT and in
the placebo group, respectively. The number of patients
that the blinded investigator considered as actively trea-
ted were nine in the ESWT group and two in the placebo
group.
The power analyses showed that the statistical tests,
used to compare the subscale of ROM and the total
CMS between ESWT and placebo groups at the final fol-
low-up, had a power respectively of 75.5% and 70.3% to
detect the observed differences. The statistical tests used
to compare the CMS values at follow-up and baseline
within the ESWT group had a power of 99.9% for the














1 55 98 Yes 1 43 61 no
2 31 39 No 2 47 79 yes
3 45 94 Yes 3 54 78 yes
4 39 69 Yes 4 57 46 no
5 29 96 Yes 5 27 30 no
6 36 87 Yes 6 52 17 no
7 45 92 Yes 7 35 45 no
8 49 61 No 8 20 23 no
9 61 73 Yes 9 40 53 no
10 36 52 No
11 41 55 No
Successful Treatment 63,7% Successful Treatment 22,3%
CMS, indicates Constant and Murley Score; ESWT, extracorporeal shock wave therapy.
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for the total score to detect the observed differences.
A telephone recall of the ESWT patients has been car-
ried out nine years after treatment and we were able to
collect data on 10 out of 11 individuals. No patient pro-
gressed to surgical intervention and two patients showed
a recurrence of shoulder pain 3 and 4 years after ESWT,
respectively. These patients were successfully treated
with a second ESWT (1) and medication for pain with a
regimen of scapulothoracic and glenohumeral range of
motion and strengthening exercise (1). Nine years after
ESWT all the patients available were satisfied with the
treatment received and would have repeated the same
therapy again.
Discussion
Thousands of ESWT for NCST are currently performed
in Europe [12], even if the available evidence does not
support the use of this technique with this indication
[10]. Because of the small number of studies on this
topic and the few application protocols tested up to now
[11-13], we re-evaluated the efficacy of low energy
ESWT for NCST using a new protocol. Indeed, it has
been clearly demonstrated that different protocols con-
siderably modify the success rate of ESWT [22].
For the first time, we have demonstrated that patients
suffering from NCST may benefit from ESWT. Our find-
ings showed a significant CMS improvement in the
ESWT but not in the control group six and twelve weeks
after treatment. Furthermore, significant CMS differ-
ences between the groups at follow-up were also noted.
The ESWT was found to be safe and well tolerated by
the patients.
The best evidence for new treatments usually comes
from randomized, placebo-controlled, double-blind studiesand our work tried to provide compelling evidence that
ESWT is effective in NCST. Our protocol included ran-
dom sequence generation, allocation concealment, and
blinding. A great effort was made to mask the real ESWT
in order to eliminate subjective bias on the part of both
experimental subjects and the experimenters. Indeed, the
ESWT masking appeared less than optimal in previous
similar studies [11,13]. Because the minimum effect size of
the CMS is not known [23], we considered a clinically sig-
nificant response a 30-point increase in the CMS [11]
which is considerably higher than the values chosen by
others to evaluate ESWT [22,23]. However, it should be
noted that the 30-point difference it’s an arbitrary cut-off,
not derived from research evidence. Interestingly, the
study achieved a 100% rate of follow-up of patients, not-
withstanding the presence of the placebo group.
Some limitations of the present investigation should
also be acknowledged. The small sample size may have
increased the risk of an underpowered randomized con-
trolled trial. However, the differences in the CMS scores
both within the ESWT group and between treatment
groups at final follow-up were highly significant and the
power analysis supported these findings, despite the
small number of patients per group. Studies are consid-
ered to be adequately powered when there is about an
80% probability the study would show a treatment effect
if it is present [24].
The short-term follow-up may have limited the
generalizability of our study, even if the same follow-up
interval was used previously in similar ESWT trials
[11,23,25]. Notably, the short follow-up was useful to de-
fine the direct effects of ESWT on the clinical course of
the condition and on the morphology of the supraspina-
tus tendon. Indeed, with a longer follow-up there might
have been confusion between the effects of the treatment
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crease the length of follow-up was the consideration that
it is ethically and psychologically difficult to obtain
informed consent to enter a study from patients present-
ing with chronic pain. The longer the duration of the
study, the fewer are the individuals that would accept the
possibility of receiving a sham treatment while suffering
pain. Moreover, it should be noted that alternatives ther-
apies are available to treat supraspinatus tendinopathy
[3], and when treatments for a disorder already exist, it
could be argued that it is unethical to create a placebo
group that will receive no treatment at all. A different
study design should be proposed to evaluate ESWT over
a longer period.
The demonstration of ESWT efficacy in the short-term
period is still a valuable finding of this investigation. In-
deed, previous studies showed satisfactory outcomes in
the short-term after other conservative therapies such as
physical therapy [26] or subacromial cortisone injection
[27-29]. However, we showed an higher improvement of
CMS in comparison to the values reported by others
treating the supraspinatus tendinopathy with ultrasounds
or rehabilitation program with the same follow-up [26].
As for the corticosteroids, there is reasonably strong evi-
dence that cortisone injection causes deleterious effects
on the tendon and the outcomes deteriorates over time
[30]. Indeed, the continued use of a local corticosteroid
is discouraged [31]. On the contrary, no detrimental
effects of ESWT for shoulder pain in the long-term
period have been reported [32,33] and this treatment
could eventually be repeated in case of recurrence of
symptoms.
Our data are in keeping with the results of a recent
study reporting significant increase in function and re-
duction of pain after low or high-energy ESWT in
patients with NCST [12]. But our findings do not agree
with the only two existing randomized, controlled stud-
ies that analyzed the efficacy of ESWT in NCST [11,13].
Indeed, Schmitt and colleagues reported significant CMS
improvements both in low energy ESWT and in the pla-
cebo group three months after treatment, but no differ-
ence in CMS between the groups was noted [11],
therefore shock waves were not recommended for
NCST. However, in this study the method for adminis-
tration of local anaesthetic involved use of a large bolus
in the subacromial region (i.e. 10 cc of mepivacaine) and
certain dosages of local anaesthetic are considered to be
therapeutic [27]. Further weakness in the sham design
and the method of assessment of the supraspinatus ten-
don with either MRI or ultrasounds must be considered.
The trial by Speed [13] analyzed medium-energy ESWT
in comparison with a placebo treatment for non-calcific
tendinopathy of the rotator cuff, and confirmed the find-
ings of Schmitt three months after the completion oftherapies. However, some weakness appears also in this
study due to the sham design. In the placebo group, the
treatment head was deflated and contact with the skin
was avoided, and no local anaesthesia was used. Since
shockwaves may cause pain and discomfort, the ESWT
masking here is less than optimal. Notwithstanding the
limitations of these studies, any comparison with our
findings is difficult because of the several variables that
define the application parameters of ESWT. The shock
wave generator, the number of impulses, the focusing of
the shockwave with respect to the tendon insertion, the
number and the interval between each treatment session,
all are important factors that have to be carefully consid-
ered [6]. It is possible that different treatment regimens
may be more effective than others [22] and, to our
knowledge, the treatment protocol we used has not been
utilized previously in a similar clinical setting.
Notably, to overcome at least in part the limitation of
a short-term follow-up we performed a recall of patients
nine years after treatments and an high satisfaction rate
with treatment received together with a low recurrence
of shoulder pain was noted.
We reported a successful treatment in 22% of our
patients in the placebo group. This finding could be
explained by the placebo effect rather than by the injec-
tion of a local anesthetic used to mask the treatment. In-
deed, it is unlikely that a small dosage of local anesthetic
into the subcutaneous fat of the shoulder would have a
therapeutic effect. In fact, it was previously demonstrated
that only higher dosages of this drug injected above the
subacromial space are effective in the treatment of
chronic rotator cuff tendinopathy [27]. It should be
noted that the regression to the mean due to the spon-
taneous improvement or fluctuations in symptoms can
lead to a false impression of the placebo effect [34].
One controlled prospective randomized trial on ESWT
for calcifying tendinopathy of the rotator cuff has
demonstrated that focusing the shock waves on the calci-
fied area rather than on the insertion of the supraspina-
tus tendon is more effective [35], but no data are
available regarding the best area to focus the shock
waves in NCST. We focused the shock waves at an area
one cm proximal to the insertion of the tendon in the
bone where areas of avascularity have been described
[36-38]. It has still not been determined whether vascu-
lar changes occur or are associated with rotator cuff
pathology [39], however, experimental studies have
demonstrated that shockwaves improve the blood supply
to the tendon tissue throughout a neovascularization
process [40] and low energy ESWT modulates the syn-
thesis of nitric oxide [41,42], a molecule that plays a crit-
ical role in the regulation of vascular tone, angiogenesis
[42], and in the degeneration of the tendon [43-45]. Re-
cently, it has been suggested that shock waves behave
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disease, even reducing the pathological angiogenesis
associated with rotator cuff disease [46]. Further thera-
peutic mechanisms of ESWT in the treatment of tendi-
nopathies have been hypothesized. ESWT have been
shown to promote healing of tendinopathies by inducing
TGF-beta1 and IGF-I [47]. However, the therapeutic
mechanism of shock waves in the treatment of supraspi-
natus tendinopathy is still uncertain.
Conclusion
ESWT was found to be safe and well-tolerated and, for
the first time, it was demonstrated that patients suffering
from NCST may benefit from low energy shock waves,
at least in the short-term. The extracorporeal shock wave
application protocol is likely to play a key-role in the
successful treatment of NCST. Future investigations
should be undertaken on the long-term effects of this
technique in NCST.
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